{"id":"W4229062082","doi":"10.1016/j.annonc.2022.03.185","title":"166MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from BEGONIA, a phase Ib/II study","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Oncology; Internal medicine; Tolerability; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004143868,0.0005549426,0.0009004042,0.0003241681,0.0001741882,0.0005394153,0.0004012604,0.0003435375,0.003613167],"category_scores_gemma":[0.000283757,0.0001895256,0.0005377175,0.0003166593,0.0002646834,0.0002923334,0.0001938491,0.001029575,0.0008055535],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006676106,"about_ca_system_score_gemma":0.0007407573,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001831226,"about_ca_topic_score_gemma":0.009141971,"domain_scores_codex":[0.9998684,0.00004754878,0.000007208951,0.00002109433,0.00001549674,0.00004032327],"domain_scores_gemma":[0.9998832,0.00002595789,0.00001674759,0.00001131576,0.000006474075,0.00005633371],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3053972,0.02323691,0.01457931,0.001983388,0.002237256,0.0004482379,0.0002921907,0.005036918,0.08602631,0.0007869562,0.01189691,0.5480784],"study_design_scores_gemma":[0.3998287,0.4324883,0.09961428,0.000433886,0.003236297,0.001628095,0.0002527313,0.004850741,0.01981037,0.0006826251,0.03708137,0.00009256344],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9827321,0.008507059,0.0002944626,0.0004080272,0.0001359559,0.0005102685,0.001545224,0.0001082434,0.0057585],"genre_scores_gemma":[0.9828828,0.006216353,0.0009567911,0.0007738553,0.00007346708,0.0003064473,0.004096807,0.00003120574,0.004662307],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003613167,"threshold_uncertainty_score":0.01208729,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1129353961526078,"score_gpt":0.4609971678987615,"score_spread":0.3480617717461537,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}